Diabetes treatment in two pregnant women with permanent neonatal diabetes mellitus due to a KCNJ11 mutation

Heterozygous activating KCNJ11 mutations are a common cause of permanent neonatal diabetes mellitus (PNDM) treated with insulin or sulfonylureas. However, only a few case reports on the treatment of women with KCNJ11-PNDM during pregnancy have been published. In the present paper, we report on two women with PNDM carrying a de novo heterozygous activating KCNJ11 mutation who were treated with a sulfonylurea and/or insulin during their pregnancies.

[1]  Kenneth L. Jones,et al.  Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study , 2018, The lancet. Diabetes & endocrinology.

[2]  M. Skopkova,et al.  Sulfonylurea vs insulin therapy in individuals with sulfonylurea‐sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control , 2018, Diabetic medicine : a journal of the British Diabetic Association.

[3]  A. Hattersley,et al.  Management of sulfonylurea‐treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer , 2017, Diabetic medicine : a journal of the British Diabetic Association.

[4]  F. Ashcroft,et al.  Fetal Macrosomia and Neonatal Hyperinsulinemic Hypoglycemia Associated With Transplacental Transfer of Sulfonylurea in a Mother With KCNJ11-Related Neonatal Diabetes , 2014, Diabetes Care.

[5]  T. Fenton,et al.  A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants , 2013, BMC Pediatrics.

[6]  T. Klupa,et al.  Sulfonylurea Use During Entire Pregnancy in Diabetes Because of KCNJ11 Mutation: A Report of Two Cases , 2012, Diabetes Care.

[7]  T. Klupa,et al.  The first case report of sulfonylurea use in a woman with permanent neonatal diabetes mellitus due to KCNJ11 mutation during a high-risk pregnancy. , 2010, The Journal of clinical endocrinology and metabolism.

[8]  A. Hattersley,et al.  Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. , 2007, The Journal of clinical endocrinology and metabolism.

[9]  F. Ashcroft,et al.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. , 2006, The New England journal of medicine.